Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-23
DOI
10.1038/s41598-018-22162-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial
- (2017) Daniel S Ory et al. LANCET
- Presymptomatic Alterations in Amino Acid Metabolism and DNA Methylation in the Cerebellum of a Murine Model of Niemann-Pick Type C Disease
- (2016) Barry E. Kennedy et al. AMERICAN JOURNAL OF PATHOLOGY
- Development of a bile acid–based newborn screen for Niemann-Pick disease type C
- (2016) Xuntian Jiang et al. Science Translational Medicine
- Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses
- (2016) Thomas Kirkegaard et al. Science Translational Medicine
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Erratum: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2015) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1
- (2014) Anand Venkatraman et al. HUMAN MOLECULAR GENETICS
- Plasma Signature of Neurological Disease in the Monogenetic Disorder Niemann-Pick Type C
- (2014) Md. Suhail Alam et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Histone Deacetylase 3 Is Necessary for Proper Brain Development
- (2014) Jordan Norwood et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
- (2013) Barbara Calamini et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Miglustat: A Review of Its Use in Niemann-Pick Disease Type C
- (2013) Katherine A. Lyseng-Williamson DRUGS
- Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood–brain barrier permeability
- (2013) Charles C. Pontikis et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones
- (2013) C. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Npc1 Acting in Neurons and Glia Is Essential for the Formation and Maintenance of CNS Myelin
- (2013) Ting Yu et al. PLoS Genetics
- HDAC4 Governs a Transcriptional Program Essential for Synaptic Plasticity and Memory
- (2012) Richard Sando et al. CELL
- Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives
- (2012) Giuseppe Giannini et al. Future Medicinal Chemistry
- Epigenetic mechanisms in neurological disease
- (2012) Mira Jakovcevski et al. NATURE MEDICINE
- Genomic Expression Analyses Reveal Lysosomal, Innate Immunity Proteins, as Disease Correlates in Murine Models of a Lysosomal Storage Disorder
- (2012) Md. Suhail Alam et al. PLoS One
- A novel mouse model of Niemann–Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations
- (2011) Robert A. Maue et al. HUMAN MOLECULAR GENETICS
- Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations
- (2011) Charina M. Ramirez et al. JOURNAL OF LIPID RESEARCH
- Unesterified Cholesterol Accumulation in Late Endosomes/Lysosomes Causes Neurodegeneration and Is Prevented by Driving Cholesterol Export from This Compartment
- (2011) A. Aqul et al. JOURNAL OF NEUROSCIENCE
- Amino acid substitution in NPC1 that abolishes cholesterol binding reproduces phenotype of complete NPC1 deficiency in mice
- (2011) X. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuroprotection by Histone Deacetylase-7 (HDAC7) Occurs by Inhibition of c-junExpression through a Deacetylase-independent Mechanism
- (2010) Chi Ma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Niemann-Pick disease type C
- (2010) Marie T Vanier Orphanet Journal of Rare Diseases
- Weekly Cyclodextrin Administration Normalizes Cholesterol Metabolism in Nearly Every Organ of the Niemann-Pick Type C1 Mouse and Markedly Prolongs Life
- (2010) Charina M Ramirez et al. PEDIATRIC RESEARCH
- Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 Disease
- (2010) F. D. Porter et al. Science Translational Medicine
- Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis
- (2009) M Griese et al. CLINICAL GENETICS
- Miglustat in adult and juvenile patients with Niemann–Pick disease type C: Long-term data from a clinical trial
- (2009) James E. Wraith et al. MOLECULAR GENETICS AND METABOLISM
- Clinical experience with miglustat therapy in pediatric patients with Niemann–Pick disease type C: A case series
- (2009) M. Pineda et al. MOLECULAR GENETICS AND METABOLISM
- Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development
- (2009) R. L. Montgomery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse
- (2009) B. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More